Study #2024-1497
A phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes - TIL) in participants with previously treated advanced endometrial cancer
MD Anderson Study Status
Enrolling
Treatment Agent
Lifileucel
Description
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Endometrial Cancer
Study phase:
Phase II
Physician name:
Amir Jazaeri
Department:
Gynecologic Oncology & Reproductive Medicine
For general questions about clinical trials:
1-866-960-0285
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.